MARATTO

article · Pan Arab Journal of Neurosurgery/Pan arab journal of neurosurgery

Ovarian serous carcinoma metastasis to the ventricular system: exceptional location report

Abstract

Background:Serous carcinoma is the most prevalent form of ovarian cancer, extensively studied and reviewed. Despite the significant research, this aggressive gynecologic neoplasm continues to have a high fatality rate. Dissemination to the brain is rare. Metastases to the cerebellum are the most common, whereas the occurrence of intra ventricular metastasis remains unreported to the best of our knowledge.Case description:We present a compelling case study involving a 48-year-old female patient who had a previous medical history of ovarian cancer, treated with bilateral salpingo-oophorectomy and adjuvant chemotherapy. Remarkably, 48 months following her initial treatment, she developed an intraventricular metastasis. Imaging revealed the presence of a multi lobulated mass within the left occipital horn. Despite undergoing a radical surgical resection, her clinical course remained highly aggressive, highlighting the challenging nature of this particular case.Conclusion:Radical surgical resection emerges as the most relevant treatment option for patients with unique metastasis to the ventricular system. This case contributes to the existing body of literature concerning the unfavorable prognosis associated with serous ovarian carcinoma, further emphasizing the importance of early detection and diagnosis awareness.

Research topics

  • Brain Metastases and Treatment
  • Glioma Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/pajn.2023.211827.1095

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.